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Available online xxxxBackground: A wide range of host restriction factors (RF) become upregulated upon HIV-1 infection to suppress
viral infectivity and may aid viremic control in vivo. This cross-sectional study evaluated HIV-1 RFs and depen-
dency factors in HIV infected individuals with progressive or non-progressive infection, as well as in early and
late treated cohorts that exhibit different viro-immunological proﬁles due to differences in timing of
treatment-initiation.
Methods: The expression proﬁle of IFIT1, MX1, APOBEC3G, SAMHD1, BST2 (encoding TETHERIN), TRIM5, MX2,
SLFN11, PAF1, PSIP1 (encoding LEDGF/p75), andNLRX1wasmeasured by qPCR in 104 HIV-1 positive individuals:
seroconverters (SRCV; n= 19), long term non-progressors (LTNP; n= 17), viremic progressors (VP; n= 12),
patients treated during seroconversion (Early treated; n= 24) or chronic infection (Late treated; n= 32), and
non-infected controls.
Findings: Expression levels of early treated HIV-1 positive individuals were signiﬁcantly upregulated in compar-
ison to late treated patients (IFIT1: p=0·0003;MX1: p=0·008; APOBEC3G: p=0·002; SAMHD1: p=0·0008;
SLFN11: p b 0·0001; BST2: p b 0·0001). Similarly, SLFN11, BST2, and SAMHD1were highly expressed in LTNPs at
comparable levels as in early treated HIV-1 positive individuals. Furthermore, SLFN11 and SAMHD1 expression
negatively correlated with total and integrated HIV-1 DNA levels.
Interpretation: Early treatment initiation maintains initial RF elevation even after a decade of ART. Elevated ex-
pression of SLFN11, BST2, and SAMHD1 in LTNP and early treated subjects implies that these RFs may be associ-
ated with spontaneous virological control.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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A variety of pattern-recognition receptors are triggered by infec-
tion with human immunodeﬁciency virus-1 (HIV-1), and rapidly ac-
tivate innate immune responses, including type I interferon (IFN)
production. Subsequently, a set of antiviral response genes, collec-
tively known as interferon-stimulated genes (ISGs), are induced
[1]. Speciﬁc ISGs subclasses, the so-called restriction factors (RF),
limit retroviral replication at distinct stages of the viral life cycle,
and may contribute to HIV-1 control in vivo. The best characterized
RFs include bone marrow stromal cell antigen 2 (BST2)/tetherin,, Medical Research Building 2,
ndekerckhove).
en access article under the CC BY-NC
. Trypsteen, E. Malatinkova,
Medicine, https://doi.org/10.1apolipoprotein B mRNA editing enzyme catalytic subunit 3G
(APOBEC3G), SAM domain and HD domain containing protein 1
(SAMHD1) and tripartite motif containing 5 (TRIM5). RFs exhibit
their anti-viral effects at different time points of the viral replication
cycle: SAMHD1 depletes the dNTP pool interfering with reverse tran-
scription, TRIM5 restricts HIV-1 early after infection by targeting the
viral capsid, APOBEC3G is known to cause hypermutation of viral se-
quences, and tetherin restricts HIV-1 replication by inhibiting viral
particle release [1,2]. Additional RFs have been described recently,
such as MX2, SLFN11, PAF1, and SERINC3/5, which interfere with nu-
clear import, protein translation of viral RNAs, early events in repli-
cation cycle and fusion, respectively [1–5]. HIV-1 has developed
various strategies to overcome the RF activity through a number of
HIV-1 accessory proteins, such as the viral infectivity factor (Vif),
viral protein U (Vpu), negative regulatory factor (Nef), and viral pro-
tein R (Vpr) [6].-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
et al., Early treated HIV-1 positive individuals demonstrate similar
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Research in context
Evidence before this study
The role of restriction factors in limiting HIV-1 replication has
been intensively investigated in vitro, however, in vivo data is
limited and often incomplete. Expression of some restriction
and antiviral factors, e.g. SLFN11, SAMHD1, and CDKN1A/
p21, has been linked to non-progressive HIV-1 infection
in vivo, in which HIV-1 positive individuals are able to maintain
undetectable or low viral load levels without therapy initiation,
the so-called elite controllers or long term non-progressors.
Only few studies have examined restriction factor profiles in
these specific HIV-1 patient cohorts and conflicting data
about their contribution to the elite controller or long term
non-progressor status exists. Therefore, additional research is
necessary to understand how varied restriction factor expres-
sion patterns impact the clinical outcomes seen in different co-
horts of HIV-1 positive individuals in order to better understand
the potential contribution of these factors to a non-progressive
phenotype.
Added value of this study
In the present study, we assessed expression levels of two an-
tiviral factors, seven restriction factors and two dependency
factors in a large number of patients (n = 104), who are
grouped within five well-defined cohorts of HIV-1 positive indi-
viduals based on differential levels of virological control and
treatment characteristics. These include seroconverters, vire-
mic progressors, long term non-progressors, early treated indi-
viduals, who initiated therapy during seroconversion, and late
treated HIV-1 positive individuals, treated during chronic infec-
tion. This is the first study to evaluate RF profile in such large
and well-characterized cohorts. Our study clearly pointed to a
signature of RF profile associated with non-progressive infec-
tion and showed that SLFN11, BST2 and, to a lesser extent
SAMHD1, were upregulated in long term non-progressors. Im-
portantly, the same restriction factors were also significantly
upregulated in early treated individuals suggesting that
SLFN11, BST2 and SAMHD1 upregulation is specifically linked
to cohorts characterized by a small reservoir size and favorable
prognosis. Moreover, this is the first study to demonstrate a
negative correlation between SLFN11, SAMHD1 levels with
total and integrated HIV-1 DNA, clearly implicating the involve-
ment of the two RFs in restricting HIV-1 reservoir.
Implications of all the available evidence
Our study and previous data consistently show the impact of
timing of treatment initiation on restriction factor expression
profiles, suggesting that early therapeutic intervention pre-
vents depletion of the early innate antiviral immune responses
in peripheral blood mononuclear cells. Additionally, the poten-
tial contribution of restriction factors SLFN11 and SAMHD1
to a non-progressive HIV-1 infection in vivo as reported previ-
ously was confirmed in this analysis. Therefore, this study
complements existing literature on the role of RFs in HIV reser-
voir restriction and provides an extensive and comprehensive
overview of multiple antiviral factors and dependency factors
profiles in HIV-infected patients with different virological and
clinical status.
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progressors (VP), ART-naïve HIV-1 positive individuals with high viral
load (VL), late ART-treated HIV-1 positive individuals and ART-naïve in-
dividuals who spontaneously control HIV-1 viremia, the so-called elite-
controllers (EC), has shown overall increased RF expression in VP as
compared to uninfected individuals, ECs and late ART-treated HIV-1
positive individuals linking upregulated RF proﬁle to high VL [7]. Inter-
estingly, restriction factor Schlafen Family Member 11 (SLFN11), which
is involved in the inhibition of viral protein synthesis, violated this typ-
ical RF proﬁle and was shown to be upregulated in ECs, therefore sug-
gesting a role in the suppression of HIV-1 replication in vivo [7].
Besides SLFN11, expression proﬁles of RF SAMHD1 and antiviral factor
CDKN1A/p21, have been investigated in ECs and compared to VP and
uninfected individuals. Both factors were shown to be upregulated in
ECs, however, this data could not be conﬁrmed in other cohorts
[8–11]. In a longitudinal study, increased RF expression levels were ob-
served during the natural course of HIV-1 infection [7,12], suggesting
that it was linked to HIV-1 viral load (VL) levels. Other ISGs have been
shown to follow a similar pattern indicating that VL and interferon pro-
duction are important drivers of RF/ISG elevation [7,12,13]. Interest-
ingly, RF PAF1, restricting HIV-1 during early events of infection, did
not show this increased levels overtime and was stably expressed sug-
gesting a restricting mechanism independent of VL and interferon in-
duction. Additionally, timing of ART initiation has been suggested to
impact host cell-intrinsic antiviral factors with increased RF expression
in early versus late treated individuals [14].
Virological control, both spontaneous and after treatment discontin-
uation, has been associated with a low viral reservoir as measured by
HIV-1 DNA [15,16]. Host RF expression may play an important role in
determining the size of the HIV-1 reservoir size as described in recent
studies showing associations between RF levels and the reservoir size
in ECs and long-term non-progressors (LTNPs) [17,18]. Additionally, a
negative correlation between these factors andHIV-1 transcriptional ac-
tivity (cell-associated HIV-1 RNA) in ART-suppressed individuals has
been described, therefore suggesting that they may contribute to the
control of viral transcription and replication during treatment [14,19].
Having the opportunity to access a large cohort of HIV-1 positive in-
dividuals with unique clinical phenotypes such as ART-naïve
seroconverters (SRCV), ART-naïve viremic progressors (VP), ART-
naïve LTNPs, early, and late ART-treated HIV-1 infected individuals, we
have comprehensively investigated the role of antiviral factors, restric-
tion factors and dependency factors,with an emphasis on their relation-
ship with virological and immunological parameters and timing of
treatment initiation. We speciﬁcally selected APOBEC3G, SAMHD1,
BST2, TRIM5 andMX2 because these RFs have been extensively investi-
gated in vitro, however comprehensive in vivo data is still lacking.
SLFN11 and PAF1, linked to EC status in vivo[7] and stable expression
proﬁle [12], respectively, were included to validate these ﬁndings in
well-characterized cohorts of HIV positive individuals. Antiviral factors
MX1 and IFIT1, well-characterized ISGs without direct HIV-1 speciﬁcity,
were selected to monitor immune activation and their relationship to
RFs expression. Additionally, two HIV-1 dependency factors, PSIP1 and
NLRX1, involved in integration [20] and repression of IFN response
[21], were included as they were expected to be linked to HIV-1 pro-
gression. Given that LTNPs represent an ideal model for spontaneous
viral control [22], we aimed to clarify whether their RF expression pat-
terns differed from other HIV-1 positive individuals in order to better
understand the potential contribution of these factors to a non-
progressive phenotype. Moreover, because some early ART-treated
individuals have shown long-term control of viral replication after stop-
ping ART, decreased virological burden in terms of HIV-1 DNA [23,24]
and enhanced immune restoration as measured by CD4/CD8 T cell
ratio, we have compared their RF levels with other groups of HIV-1 pos-
itive individuals to assess the impact of early treatment intervention onet al., Early treated HIV-1 positive individuals demonstrate similar
016/j.ebiom.2019.02.006
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Fig. 1. Patient cohorts. Blue arrows represent time of sampling. Viral load levels of ART-
naïve HIV-1 positive individuals at time of sampling are depicted in Supplementary
Fig. 1. *PHI: primary HIV-1 infection; ART: antiretroviral therapy; SRCV: seroconverters;
VP: viremic progressors; LTNP: long-term non-progressors. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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LTNPs.2. Materials and methods
2.1. Patient cohorts
HIV-1 positive subjects were recruited between 2014 and 2017 from
two clinical centers, the Ian Charleson Day Centre, Royal Free Hospital,
London, United Kingdom and the AIDS Reference Center, Ghent Univer-
sity Hospital, Ghent, Belgium. Peripheral blood mononuclear cells
(PBMCs) were obtained from 104 HIV-1 positive individuals at one
time-point from 5 cohorts based on their disease status: 1) ART-naïve
SRCV (n=19), who were sampled during the acute phase of infection;
2) ART-naïve LTNPs (n = 17) who maintained HIV-1 viremia ≤1000
copies/ ml and CD4+ T cells N500 cells/mm3 over N7 years post-
infection and 3) long-term-ART treated individuals who had initiated
ART during seroconversion (early treated; n = 24) or 4) the chronic
phase of infection (late treated; n= 32), as previously described [23],
and 5) ART-naïve VP (n = 12) with long-term VL N 3000 HIV-1 cop-
ies/ml. Uninfected healthy controls (n = 14) were sampled from the
Red Cross Flanders (Belgium) as a control group. Appropriate sampleTable 1
Clinical characteristics and virological markers of patient cohorts.
SRCV⁎ VP⁎
Clinical characteristics n= 19 n = 12
Age (yrs) 35 (29–44) 43 (34–46)
Total cART (yrs) 0 0
Total VL suppression (yrs) 0 0
log VL zenith (copies/ml) 6.3 (5.3–6.5) 4.3 (4.1–4.7)
CD4 nadir (cells/μl) 475 (311–592) 544 (431–626
CD4 at collection (cells/μl) 475 (311–607) 601 (562–643
CD4/CD8 0.54 (0.4–0.7) 0.51 (0.4–0.7)
Viral reservoir markers
total HIV-1 DNA (c/M PBMC) 1846 (624–4966) 385 (297–132
Integrated HIV-1 DNA (c/M PBMC) 165.7 (113.3–628.1) 75.5 (48.5–24
CA HIV-1 usRNA (c/M PBMC) 15.5 (0.9–100.6) 29 (9.8–402.5
2-LTR circles (c/M PBMC) 5.2 (3.9–14.8) 1.9 (0.9–3.0)
⁎ Values are reported as median (IQR); SRCV: seroconverters; VP: viremic progressors; LTNP
ciated; usRNA: unspliced RNA; ART: antiretroviral therapy.
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power calculation for an expected difference of 50% in expression levels
resulted in a minimum cohort size of 12 patients; given 80% power,
0·05 signiﬁcance level and standard variation of gene expression levels
in patient cohorts.
The Ethical Committees of Ghent University Hospital and of the
Royal Free Hospital approved this study (reference numbers:
B670201317826/B670201733030 and 13/LO/0729). All study subjects
gave written informed consent. The subject cohorts are described in
Fig. 1 and details on study design and inclusion criteria have been de-
scribed previously [23]. Baseline characteristics and clinical parameters
(duration of ART, VL zenith, CD4 T cell count at sampling, CD4 nadir and
CD4/CD8 T cell ratio at sampling) are summarized in Table 1.
2.2. Peripheral blood mononuclear cells (PBMCs)
Blood was collected from all participants (n= 118) at a single time
point. PBMCs were isolated from freshwhole blood using density gradi-
ent centrifugation with Lymphoprep (ELITech Group, Belgium) and
stored in freezingmedia (Fetal Calf Serum (FCS)+10% dimethyl sulfox-
ide (DMSO)).
2.3. Primers
Primers for reference genes and MX1 were found in RTPrimerDB
(RRID: SCR_007106), a freely accessible database for real-time PCR
primers and probes [26]. APOBEC3G and SAMHD1 assays were commer-
cially available (Bio-Rad, Belgium), SLFN11 and IFIT1 assays were de-
scribed in literature [27,28], and primers for other restriction and
dependency factors were designedmanually using PrimerXL, a pipeline
based on Primer3with in silico assay validation [29,30]. To check in silico
target speciﬁcity, primers were blasted. Primers used are listed in Sup-
plementary Table 1 (Table S1) and were ordered at Integrated DNA
Technologies (IDT, Belgium).
2.4. Quantitative real-time PCR (qPCR)
RNAwas extracted from 107 PBMCs per sample (RNA innuprepmini
kit, Analytik, Germany) and eluted into 30 μl nuclease-freewater. Geno-
mic DNA (gDNA) was removed in a column-based manner. RNA con-
centration was determined using the Qubit Fluorometer (Invitrogen,
CA, USA) and one microgram of total RNA was reverse transcribed
into cDNA using the qScript cDNA SuperMix (Quantabio, MA, USA) ac-
cording to the manufacturer's protocol. cDNA was diluted to a concen-
tration of 10 ng/μl and 20 ng was used in a 10 μl real-time PCRLTNP⁎ Early treated⁎ Late treated⁎
n = 17 n = 24 n = 32
49 (38–51) 44 (41–49) 48 (45–53)
0 10.7 (8.4–11.99) 9.8 (6.1–14.7)
0 10.3 (8.1–11.3) 6.5 (5.0–10.4)
2.5 (2.2–2.8) 5.5 (5.0–5.9) 4.9 (4.2–5.5)
) 624 (562–693) 391 (280–485) 155 (51–266)
) 793 (685–1010) 714 (645–994) 625 (484–889)
0.91 (0.8–1.5) 1.10 (0.7–1.3) 0.74 (0.6–0.9)
0) 48 (20.2–56.5) 90 (34–124) 137 (56.1–219.2)
6.9) 2.82 (0–15.84) 18.7 (9.6–58.2) 58.7 (31.5–91.8)
) 0.4 (0.3–3.5) 1.5 (0.3–3.7) 6.1 (0–10.1)
0.8 (0.6–2.7) 1.8 (0–3.4) 1.3 (0–2.2)
: long-term non-progressors; PBMCs: peripheral blood mononuclear cells; CA: cell-asso-
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Fig. 2. Antiviral factor, HIV-1 speciﬁc restriction factor and dependency factor expression proﬁle in different cohorts of HIV-1 positive individuals. Boxplots showing normalized relative
quantity (NRQ) levels for IFIT1,MX1,APOBEC3G,MX2, TRIM5, SLFN11, BST2, SAMHD1, PAF1, PSIP1 andNLRX1 in uninfected, ART-naïve (SRCV, VP and LTNP) andART-treated (Early and Late)
HIV-1 positive individuals. Kruskal-Wallis analysis was performed and signiﬁcant p-values (p b 0·05) are marked in red.*NRQ: Normalized Relative Quantity. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Applied Science, Belgium) for restriction factors and dependency fac-
tors. A second cDNA dilution (2.5 ng/μl) was generated for reference
genemeasurement as lower input is sufﬁcient for their adequate analy-
sis. Per reaction, 5 μl SYBR Green Master Mix, 2.5 μl H2O and 250 nM of
each primerwere added and every reactionwas performed in duplicate.
Cycling conditions on LightCycler 480 (Roche Applied Science,
Germany) were 95 °C for 5 min, 45 ampliﬁcation cycles of 95 °C for
10s, 58 °C for 30s and 72 °C for 30s. A melting curve from 60 °C to 95
°C was run and melting curve analysis was performed with
LightCycler480 software to determine assay speciﬁcity. Samples with
aberrant melting curves were excluded from the analysis. The stability
of 8 reference genes: actin beta (ACTB), glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), TATA-box binding protein (TBP), beta-2-
microglobulin (B2M), tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta (YWHAZ), procollagen-lysine,
2-oxoglutarate 5-dioxygenase 1 (PLOD1), hydroxymethylbilane syn-
thase (HMBS) and ubiquitin C (UBC) was determined on a subset of
samples and the three most stable reference genes, ACTB, GAPDH and
YWHAZ, were selected with the GeNorm algorithm for normalization
[31]. PCR efﬁciency of each primer pair was calculated using a pooled
sample cDNA standard curve and applying formula: 10–1/slope. Gene ex-
pression analysis was performed with qbasePLUS software from
Biogazelle [32] allowing to perform automated normalization, PCR efﬁ-
ciency calculation and adequate inter-run calibration. Normalization
factors are calculated within this software based on the geometric
mean of relative quantities (RQ) of the selected reference genes. Rela-
tive gene expression values of RF, dependency factors and ISGs are
expressed as normalized relative quantities (NRQ) [33].
2.5. Quantiﬁcation of the HIV-1 reservoir, ongoing replication and
transcription
Total HIV-1 DNA, integrated HIV-1 DNA, circular 2-long terminal re-
peats (2-LTR) and CA HIV-1 usRNA analyses were performed on 82
samples included in this study from a previous analysis [23] and the
subsequently remaining 22 sampleswere analyzedwith the same tech-
nology listed in Supplementary Table 2 (Table S2).
2.6. Total and integrated HIV-1 DNA
Brieﬂy, total genomic DNA was extracted from 107 PBMCs using
DNeasy Blood & Tissue Kit (Qiagen, The Netherlands). Restriction diges-
tion and ddPCR reactions were performed as described previously
[34,35]. For normalization, reference gene ribonuclease P/MRP subunit
p30 (RPP30) was used and total HIV-1 DNA quantiﬁcation was com-
pleted with ddpcRquant, an in-house developed software [36].
To quantify integrated HIV-1 DNA, the repetitive sampling Alu-HIV
PCR method was applied [37]. Alu-HIV PCR is a nested PCR, including
a ﬁrst round with an HIV-1 speciﬁc reverse primer in the HIV-1 gag re-
gion and a human Alu-speciﬁc forward primer. This reaction is per-
formed in 40 replicates. Additionally, 20 replicates for background
quantiﬁcation using only the HIV-1 gag primer were included. This
method was performed as described previously [37]. In contrary to pre-
vious published results [23], the correction factor of 0.1 for integrated
HIV-1 DNA values was not applied as recently described [38].
2.7. Episomal HIV-1 2-LTR circles
2-LTR quantiﬁcation by ddPCR was performed as previously de-
scribed [23,34]. Brieﬂy, plasmid DNA (pDNA) was isolated using the
QIAprep Spin Miniprep kit (Qiagen) from 107 PBMCs and pDNA was
eluted into 25 μl to increase DNA concentration. pSIF1-H1-Puro non-
HIV plasmid (System Biosciences, CA, USA) with determined amount
of copieswas spiked to the samples as an internal control for copy num-
ber normalization as previously described [34]. The internal referencePlease cite this article as: C. Van Hecke, W. Trypsteen, E. Malatinkova,
restriction factor expression proﬁle a..., EBioMedicine, https://doi.org/10.1plasmid contained a woodchuck hepatitis virus posttranscriptional reg-
ulatory element (WPRE) and WPRE primers and probe were used for
quantiﬁcation [39]. Primers used are listed in Supplementary Table 2
(Table S2) [39,40].
2.8. Cell-associated HIV-1 usRNA
One microgram of total RNA was reverse-transcribed into cDNA
using the qScript cDNA SuperMix (Quantabio). ddPCR quantiﬁcation
of CAHIV-1 usRNAwas performed as described previously [41,42]. Nor-
malization of cDNA input was done with the abovementioned normali-
zation strategy in the qPCR section. ddPCR concentration values for CA
HIV-1 usRNA were calculated using Quantasoft and adequate threshold
determination was performed with ddpcRquant [36]. For normaliza-
tion, rawCAHIV-1 usRNA concentration valueswere dividedby the cor-
responding normalization factors [41].
2.9. Statistical analysis
Non-parametric Kruskal-Wallis with post-hoc Nemenyi statistical
analysis was performed. Tukey correction was used for multiple com-
parisons. Spearman correlation analysis was performed to deﬁne signif-
icant correlations between RF, dependency factors, ISGs and
immunological and virological reservoir parameters. After initial uni-
variate analyses, multivariate principal component analysis (PCA) anal-
ysis was performed. We used for statistical analyses and graphing R
software with the following packages: PMCMR, Hmisc, graphics,
ggplot2, and corrplot.
3. Results
3.1. Study participants
Fourteen HIV negative and 104 HIV-1 positive individuals were en-
rolled into this cross-sectional study [23]. HIV-1 positive individuals
comprised 3 cohorts of ART-naïve and 2 cohorts of ART-treated individ-
uals (Fig. 1). ART-naïve individuals included: 1) SRCV (n=19), patients
diagnosed during acute seroconversion characterized by high VL, 2) VP
(n = 12), patients diagnosed during chronic infection, 3) LTNPs (n =
17), individuals capable of maintaining high CD4 count and undetect-
able or low VL without ART initiation (Supplementary Fig. 1). ART-
aviremic HIV-1 positive individuals included individuals that initiated
treatment: 4) during seroconversion (Early treated, n= 24), or 5) dur-
ing chronic infection (Late treated, n = 32) (Fig. 1). Their clinical and
laboratory characteristics are described in Table 1.
3.2. SLFN11, BST2 and SAMHD1 are associated with a LTNP phenotype
LTNPs control HIV-1 replication in the absence of ART and display a
low viral reservoir [15,23]. Hence, these individuals are frequently stud-
ied as amodel of functional cure, as deﬁned by long-term control of HIV-
1 replication in the absence of ART or as in post-treatment controllers
after ART discontinuation [43,44].Mechanisms that drive this type of vi-
rological control are not fully elucidated. Host RF besides the previously
described SLFN11[7] could play a signiﬁcant role inHIV-1 suppression in
these groups. To comprehensively address the role of multiple antiviral
factors and dependency factors in VL control, we have analyzed the ex-
pression proﬁle of IFIT1,MX1, APOBEC3G, SAMHD1, BST2, TRIM5, SLFN11,
MX2, PAF1, PSIP1, and NLRX1 in HIV-1 positive individuals with various
degrees of virological control, such as viremic or aviremic subjects that
are either spontaneous controllers or ART-mediated controllers.
IFIT1 and MX1 are well-characterized ISGs but are not RFs directly
acting on HIV-1 life cycle and their expression proﬁle was assessed in
this study as a marker of interferon exposure. Differences between ex-
pression proﬁles of IFIT1, MX1 and HIV-1-speciﬁc RFs could reveal
whether and to what extend speciﬁc HIV-1 RF responses are driven byet al., Early treated HIV-1 positive individuals demonstrate similar
016/j.ebiom.2019.02.006
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7C. Van Hecke et al. / EBioMedicine xxx (2019) xxxinterferon exposure. Univariate analysis showed signiﬁcant upregula-
tion of IFIT1 and MX1 in SRCV and VP, both cohorts characterized by
high viremia, as compared to LTNPs and HIV negative individuals
(Fig. 2; Supplementary Fig. 1). Furthermore, similar expression proﬁles
were present for several but not all RF directly acting on HIV-1 lifecycle
such as APOBEC3G, MX2 and TRIM5. These RF displayed also elevated
levels in SRCV (p b 0·0001, p = 0·001 and p = 0·005, respectively)
and VP (p = 0·001 and p = 0·003, respectively) as compared to HIV
negative individuals (Fig. 2). This expression proﬁle was not seen for
SLFN11, BST2, SAMHD1 and PAF1 and dependency factors PSIP1 and
NLRX1, implying that VL levels may selectively drive the expression of
only some RF and ISGs.
In LTNPs, SLFN11 and BST2 levels were increased signiﬁcantly as
compared to HIV negative individuals (p=0·01 and p=0·04, respec-
tively, Fig. 2). SLFN11 and BST2 displayed also slightly elevated expres-
sion levels in LTNPs in comparison to SRCV and VP, although not
reaching statistical signiﬁcance in most of the cases. Similarly,
SAMHD1 expression was boosted in some LTNPs, but overall did not
demonstrate signiﬁcant upregulation (p = 0·09 compared to HIV
negative individuals). Moreover, both, SLFN11 and BST2, also demon-
strated signiﬁcantly elevated levels in LTNP as compared to late treated
individuals (p b 0·0001 and p= 0·0006; Fig. 2) pointing to the associ-
ation of elevated SLFN11 and BST2 with spontaneously induced non-
progressive phenotype. Taken together, overall increased levels of
SLFN11 and BST2 in LTNPs suggest their potential contribution in viral
load control.
Beyond theRFs that correlatewith VL or those linked to LTNPpheno-
type, our data demonstrate that additional dependency factors such as
PSIP1 and NLRX1 may be associated with lack of virological control.
PSIP1 encodes an integrase dependency factor (LEDGF/p75) [45,46]
and is not linked to VL or IFN response. In this study, it was found to
be stably expressed in HIV negative individuals, SRCV and LTNPs,
although signiﬁcantly downregulated in VP as compared to SRCV and
LTNPs (p= 0·003 and p b 0·0001, respectively) (Fig. 2). Surprisingly,
PAF1, a RF manifesting its antiviral activity early in the replication
cycle [47], showed a similar expression proﬁle with comparable levels
in the different cohorts, except for VP in whom it was downregulated,
suggesting the association of PSIP1 and PAF1, and viremic progression
(Fig. 2). NLRX1 sequesters the DNA sensing molecule STING, stimulator
of interferon genes, thus inhibiting IFN response. Therefore, we hypoth-
esized that NLRX1 could also be associated to viremic progression. Sur-
prisingly, NLRX1 was not differentially expressed in VP, although
upregulation in SRCV and early treated individuals was detected as
compared to uninfected individuals (p = 0·0003 and p b 0·0001,
respectively). Early treated HIV positive individuals also demonstrated
a trend for NLRX1 upregulation as compared to late treated individuals,
however not signiﬁcantly, suggesting a different IFN regulation mecha-
nism in both ART-treated cohorts.
3.3. Restriction factor levels remain increased in early treated HIV-1
patients after a decade of ART
Current WHO guidelines recommend immediate treatment initia-
tion after the acquisition of HIV-1 infection. Our previous study, per-
formed in the same HIV-1 cohorts, demonstrated a beneﬁcial impact
of early treatment a decade after ART initiation on immunovirological
markers, such as CD4/CD8 ratio, total and integrated HIV-1 DNA andFig. 3. Correlation analysis of antiviral, HIV-1 speciﬁc restriction and dependency factor exp
(a) Correlation plot illustrating relations between antiviral, HIV-1 speciﬁc RF and depend
individuals (combined data of SRCV, VP, LTNP, Early and Late treated individuals). Spearman c
and red, respectively. Non-signiﬁcant p-values (p N 0·05) are indicated with an X. (b) Spearm
positive individuals (combined data of SRCV, VP, LTNP, Early and Late treated individuals). (c)
individuals (combined data of SRCV, VP, LTNP, Early and Late treated individuals). (For interpr
version of this article.)
Please cite this article as: C. Van Hecke, W. Trypsteen, E. Malatinkova,
restriction factor expression proﬁle a..., EBioMedicine, https://doi.org/10.1CAHIV-1 usRNA [23].We hypothesized that the timing of treatment ini-
tiation could also affect RF levels and therefore allow us to distinguish
between early and late treated individuals, and to allow us for direct
comparison of RF proﬁle in ART-suppressed controllers and in ART-
naïve spontaneous controllers (LTNP). Generally, similar expression
proﬁles are seen for antiviral factors linked to VL (IFIT1,MX1, APOBEC3G,
MX2 and TRIM5) in uninfected individuals and late treated HIV positive
individuals. Thus, late treated individuals do not demonstrate any
increase or decrease in RF proﬁle as compared to uninfected subjects
indicating that when ART is initiated during chronic infection, expres-
sion levels of antiviral factors are normalized to levels observed in HIV
negative individuals. SRCV and VP demonstrated a highly signiﬁcant
upregulation for IFIT1, MX1, APOBEC3G and MX2 as compared to
late but not early treated individuals ((SRCV: p b 0·0001, p b 0·0001,
p b 0·0001, and p b 0·0001, respectively) and (VP: p b 0·0001, p b
0·0001, p = 0·006, p = 0·0002, respectively; Fig. 2)). Similarly,
TRIM5 upregulation was detected in SRCV as compared to late and not
early treated HIV positive individuals (p = 0·002), suggesting differ-
ences in RF proﬁles imposed by time of ART initiation. Interestingly,
early treated HIV-1 positive individuals show increased expression
levels for IFIT1, MX1, SLFN11, BST2, SAMHD1, and APOBEC3G compared
to late treated individuals (p = 0·0003, p = 0·008, p b 0·0001, p b
0·0001, p = 0·0008, p = 0·002, respectively), even after a decade of
ART (Fig. 2). In addition, SLFN11, BST2, SAMHD1 and APOBEC3G, but
not IFIT1 and MX1, demonstrated higher expression levels in early
treated individuals as compared to uninfected individuals (p b 0·0001,
p=0·01, p=0·0005, and p=0·0005). Furthermore,MX2 expression
exhibits the same trend, although no signiﬁcant upregulation in early
treated individuals could be detected.
Overall, this data suggests that RFs linked to HIV-1 control in this
study, namely SLFN11, BST2 and SAMHD1, show similar upregulation
in early treated HIV-1 positive individuals as in LTNPs. Unlike in
LTNPs, IFIT1, MX1 and APOBEC3G, antiviral factors driven by VL, also
showed signiﬁcant upregulation in early treated individuals (Fig. 2) sug-
gesting that initiation of ART during acute infection affects expression of
both antiviral factors driven by VL or linked to non-progression. Alto-
gether, this data points to an impact of early treatment in maintaining
innate antiviral responses over the long-term.3.4. IFIT1, MX1, APOBEC3G, MX2 and TRIM5 expression is associated with
high viral load
Initial univariate analysis revealed that IFIT1, MX1, APOBEC3G, MX2
and TRIM5 demonstrated increased expression levels in cohorts of HIV
positive individuals characterized by high VL. To further explore this rela-
tionship, a spearman correlation analysis of combined data of all cohorts
(SRCV, VP, LTNP, Early treated and Late treated) was performed and de-
tected positive correlations between IFIT1, MX1, APOBEC3G, MX2, and
TRIM5, andVL (Fig. 3a andb), suggesting that indeed increasedVL induces
antiviral factors IFIT1 and MX1 and several RFs directly acting on HIV-1
lifecycle. On the contrary, SLFN11 and SAMHD1, RFs linked to LTNP status
exhibited a negative correlation with viral reservoir marker, total HIV-1
DNA (p= 0·02 and p= 0·01, respectively, Fig. 3c). For SLFN11, a signif-
icant negative correlation with integrated HIV-1 DNA was also observed
(Fig. 3a). Thus, these data suggest that SLFN11 and SAMHD1 could contrib-
ute to reduction of viral reservoir size in HIV positive individuals.ression levels with virological and viral reservoir markers in HIV-1 positive individuals.
ency factor expression levels, and different viral reservoir markers in HIV-1 positive
orrelation analysis was performed. Positive and negative correlations are depicted in blue
an correlation plots for antiviral and HIV-1 speciﬁc RF expression with viral load in HIV-1
Spearman correlation plots for SLFN11/SAMHD1with total HIV-1 DNA in HIV-1 positive
etation of the references to colour in this ﬁgure legend, the reader is referred to the web
et al., Early treated HIV-1 positive individuals demonstrate similar
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Fig. 5. Antiviral, HIV-1 speciﬁc restriction and dependency factors associated with CD4 count in ART-treated HIV-1 positive individuals. (a) Spearman correlation plot illustrating
correlations between CD4 count/nadir, antiviral, RF and dependency factors in both early and late ART-treated HIV-1 positive individuals. (b) Spearman correlation plots for SLFN11
and CD4 count/nadir.
9C. Van Hecke et al. / EBioMedicine xxx (2019) xxx3.5. SLFN11 and SAMHD1 expression is linked to a smaller viral reservoir in
ART-naïve patients
Similarly as in all cohorts combined, negative correlations were
found in ART-naïve HIV-1 positive individuals, comprising SRCV, VP
and LTNPs between SLFN11, SAMHD1, and HIV-1 persistence markers.
Both, SLFN11 and SAMHD1 were negatively correlated with VL zenith,
total and integrated HIV-1 DNA (SLFN11: ρ=−0·35, ρ=−0·41 and
− 0·30, resp.; SAMHD1: ρ=−0·31, ρ=−0·35 and− 0·31, respec-
tively), showing that higher SLFN11/SAMHD1 expressionwas associated
with lower VL and smaller viral reservoir in ART-naïve HIV-1 positive
individuals (Fig. 4a and b). Additionally, a negative correlation was
found for SLFN11 and BST2, with VL speciﬁcally in LTNP (ρ = −0·63
and ρ = −0·55, resp. Fig. 4c and Supplementary Fig. 2). These dataFig. 4. Correlation analysis of antiviral, HIV-1 speciﬁc restriction and dependency factor exp
individuals. (a) Correlation plot illustrating antiviral, HIV-1 speciﬁc RF and dependency facto
ART-naïve HIV-1 positive individuals comprising SRCV, VP and LTNP. (b) Spearman correlation
DNA in ART-naïve HIV-1 positive individuals (SRCV, VP and LTNP) (c) Correlation plot illustra
and viral reservoir markers in LTNPs. Spearman correlation analysis was performed. Positive
values (p N 0·05) are indicated with an X. (For interpretation of the references to colour in thi
Please cite this article as: C. Van Hecke, W. Trypsteen, E. Malatinkova,
restriction factor expression proﬁle a..., EBioMedicine, https://doi.org/10.1suggest that SLFN11, SAMHD1 and BST2 could play a role in reducing
viral load and therefore contribute to virological control.
3.6. The CD4 T cell count is positively correlatedwith restriction factor levels
in patients on ART
The CD4 T cell count/nadir is a prognostic marker for HIV-1 disease
progression, with high CD4 count/nadir linked to a favorable disease
outcome. The CD4 T cell count is routinely monitored for ART efﬁcacy
[48] and has shown enhanced recovery in early versus late treated
individuals [49]. We were therefore interested to determine whether
RF levels in ART-naïve or -treated individuals were linked to the
CD4 T cell count/nadir and whether it might be used as a marker of
disease progression. Interestingly, the CD4 T cell count/nadirression levels with virological and viral reservoir markers in ART-naïve HIV-1 positive
r expression levels with virological and viral reservoir markers using combined data of
analysis depicting negative correlations for SLFN11/SAMHD1 with total/integrated HIV-1
ting antiviral, HIV-1 speciﬁc RF and dependency factor expression levels with virological
and negative correlations are depicted in blue and red, respectively. Non-signiﬁcant p-
s ﬁgure legend, the reader is referred to the web version of this article.)
et al., Early treated HIV-1 positive individuals demonstrate similar
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10 C. Van Hecke et al. / EBioMedicine xxx (2019) xxxshowed a positive correlation with expression levels of IFIT1, MX1,
APOBEC3G, SAMHD1, SLFN11, and BST2 in individuals on ART (Fig. 5a
and b). The same antiviral factors were also signiﬁcantly
upregulated in early versus late treated individuals and some of
them (SLFN11, BST2, and SAMHD1) were strongly linked to spontane-
ous VL control (LTNPs). This data suggests that ART-treated individ-
uals displaying increased RF levels are associated with better
immune preservation.
4. Discussion
An in-depth characterization of several antiviral and dependency
factor proﬁles in cohorts of HIV-1 positive individuals with different
levels of virological control and treatment characteristics could uncover
their role in controlling HIV-1 replication in vivo, in particular when
comparing viremic to spontaneously and ART-suppressed controllers.
Our study described a signiﬁcant elevation of IFIT1,MX1, APOBEC3G,
MX2 and TRIM5 expression, driven by HIV-1 viral load, in SRCV and VP.
An earlier report has described such a modest positive correlation be-
tween expression of antiviral factors and VL [7]. Our data similarly sug-
gest that viral load drives elevation of several antiviral factors and HIV-1
speciﬁc RF, conﬁrming previously published results that VL is one of the
major drivers of RF elevation in vivo [7,50].
Various mechanisms have been suggested as contributing to non-
progressive infection in vivo, such as protective human leukocyte anti-
gen (HLA) class I alleles including HLA-B*57, HLA-B*27 among others
[51]. However, not all LTNPs carry these protective alleles, therefore ad-
ditional immune responses associated with host antiviral factors could
affect viral replication. In our cohort, only two LTNPs expressed HLA-
B*57 or *27 alleles, while higher levels of SFLN11 and BST2 were linked
to lower VL in the entire LTNP cohort. In previous reports, both SLFN11
and SAMHD1 have been suggested to contribute to viral control in vivo
in ECs/LTNPs [7–9]. SLFN11 restricts HIV-1 mRNA translation, probably
by occupying tRNA, thereby limiting its availability for HIV-1 protein
synthesis [52]. In contrast to our data, a previous study found compara-
ble levels of SLFN11 expression between ECs and HIV negative individ-
uals [7]. An essential disparity between the present and previous
studies [7] includes some of the characteristics of the HIV negative co-
hort,whichwere unexposed and highlyHIV-exposed seronegative indi-
viduals, respectively. SLFN11 levelswere signiﬁcantlymore expressed in
highly HIV-1 exposed individuals [7], suggesting that HIV-1 exposure
without actual infection could increase SLFN11 levels as a protective
mechanism. Previously published data shows that CD4 T cells from
ECs/LTNPs are more refractory to ex vivo HIV-1 infection in comparison
to VP, therefore upregulation of SLFN11 could also play a beneﬁcial role
in protecting cells from infection [11,53].
Both RFs, SLFN11 and SAMHD1, showed negative correlations with
VL and reservoirmarkers (total and integratedHIV-1DNA). Both factors
exhibited highest levels among LTNPs and early treated individuals,
characterized by low viral load levels, suggesting that SAMHD1 and
SLFN11 could contribute to the beneﬁcial outcome in these individuals.
SAMHD1 interferes with HIV-1 replication by depleting the dNTP pool
and thus hampers reverse transcription [2]. In terms of SAMHD1, con-
ﬂicting data exists about its contribution to the EC or LTNP status.
Some studies have described upregulated SAMHD1 levels in EC/LTNPs
in contrast to others [8,9]. Our data does not reveal signiﬁcant
SAMHD1 elevation in LTNPs although a trend was noted. This ﬁnding
combined with the negative correlation between VL and viral reservoir
markers is however suggestive for SAMHD1 contribution to viral control
in vivo.
An important limitation of our study is the descriptive type of data
from our patient cohorts and additional research is critical to conﬁrm
the potential roles of SLFN11, BST2 and SAMHD1 in viral control in vivo.
Moreover, as some cohorts (VP and Early treated) were not sampled
from both centers (London, UK and Ghent, Belgium), we cannot
completely exclude a batch effect, however, Principal ComponentPlease cite this article as: C. Van Hecke, W. Trypsteen, E. Malatinkova,
restriction factor expression proﬁle a..., EBioMedicine, https://doi.org/10.1Analysis (PCA) did not demonstrate substantial differences based on
sampling center (London, UK or Ghent, Belgium) for virological/immu-
nological characteristics within cohorts sampled at both centers (SRCV,
LTNP and late treated HIV positive individuals) (data not shown). Fur-
thermore, given that only restriction factor mRNA levels were analyzed,
it is possible that protein levels do not reﬂect mRNA expression
completely, although SLFN11 protein levels were found to mirror
SLFN11mRNA levels [7].
HIV accessory proteins can counteract antiviral effects mediated by
host RF, although mechanisms have not yet been identiﬁed for all of
them. Vif, Vpx and Vpu are able to counteract APOBEC3G, SAMHD1 and
BST2, respectively. In contrast to Vif and Vpu, both encoded by HIV-1,
Vpx is only encoded by HIV-2, thus HIV-1 cannot counteract SAMHD1
activity [2]. This could be a possible mechanism explaining why
APOBEC3G, efﬁciently counteracted by Vif, is not able to limit viral load
levels in comparison to SLFN11 and SAMHD1 lacking an identiﬁed
counteracting mechanism by HIV-1. However, caution should be taken
in interpreting these results, aswe cannot establish a causal relationship
for SLFN11 and SAMHD1 in diminishing the viral reservoir size. Addi-
tional research focusing on functional mechanisms is therefore
required.
Both, early and late ART-suppressed individuals are characterized by
undetectable VL, thus, comparable RF levels would be expected if viral
load levels were the major driver of IFN production and RF elevation.
However, univariate analyses have revealed distinct expression proﬁle
for antiviral factors in early versus late treated HIV-1 positive individ-
uals. Surprisingly, early treated subjects expressed higher IFIT1, MX1,
APOBEC3G, SLFN11, SAMHD1 and BST2 levels as compared to the late
treated ones. Some of them were also upregulated in LTNPs, revealing
similarities between early treated patients and LTNPs, such as signiﬁ-
cantly upregulated SLFN11, SAMHD1 and BST2. IFIT1,MX1 and APOBEC3G
levelswere also signiﬁcantly upregulated in early treated HIV-1 individ-
uals suggesting that these responses remain intact in the long-term
thanks to early treatment initiation. Our ﬁndings complement an earlier
report in which increased expression of antiviral factors, including
SAMHD1 and BST2, has been linked to early treatment [14]. However,
no signiﬁcant expression elevation for APOBEC3G and SLFN11 has been
previously observed in early treated individuals. These dissimilarities
may be related to the distinct cell type (CD4 T cells [14] versus PBMCs)
or timing of sample collection used in the studies. We have collected
blood after median of ten years on ART in comparison to 1–2 years
post-ART initiation [14]. Overall, this data suggests that early treatment
maintains initial RF elevation even after a decade of ART initiation.
In summary, our data show that IFIT1, MX1, APOBEC3G, MX2 and
TRIM5 are linkedwithHIV-1VL and thus are highly expressed in viremic
HIV-1 positive individuals, characterized by high VL levels. Contrary,
SLFN11, BST2 and, to a lesser extent SAMHD1, are upregulated in
aviremic individuals (LTNPs). Moreover, timing of treatment initiation
was found to impact RF levels such that signiﬁcantly elevated
APOBEC3G, BST2, SAMHD1 and SLFN11 were present in early ART-
treated subjects implying that early therapeutic intervention prevents
depletion of innate antiviral responses which was observed in late
treated individuals. We conclude that SLFN11, BST2 and SAMHD1 form
a restriction factor signature associated with protection from disease
progression. Induction of SLFN11 and SAMHD1 could limit viral load
and viral reservoir size but direction of causality needs to be experimen-
tally validated. Information gained will be useful for the design of novel
antiviral therapeutics.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.02.006.
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